Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Nature

Volumn 534, Issue 7607, 2016, Pages 341-346

  Abraham, Sheela A ^a   Hopcroft, Lisa E M ^a   Carrick, Emma ^b   Drotar, Mark E ^a   Dunn, Karen ^a   Williamson, Andrew J K ^b   Korfi, Koorosh ^a   Baquero, Pablo ^a   Park, Laura E ^a   Scott, Mary T ^a   Pellicano, Francesca ^a   Pierce, Andrew ^b   Copland, Mhairi ^a   Nourse, Craig ^a   Grimmond, Sean M ^c   Vetrie, David ^a   Whetton, Anthony D ^b   Holyoake, Tessa L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BROMODOMAIN INHIBITOR; CD133 ANTIGEN; CD34 ANTIGEN; CPI 0610; CPI 203; DASATINIB; IDASANUTLIN; IMATINIB; MYC PROTEIN; NILOTINIB; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; RITA; UNCLASSIFIED DRUG; [2 (4 TERT BUTYL 2 ETHOXYPHENYL) 4,5 BIS(4 CHLOROPHENYL) 4,5 DIHYDRO 4,5 DIMETHYL 1H IMIDAZOL 1 YL][4 [3 (METHYLSULFONYL)PROPYL] 1 PIPERAZINYL]METHANONE; ACETAMIDE DERIVATIVE; AZEPINE DERIVATIVE; CPI203; DNA BINDING PROTEIN; IMIDAZOLINE DERIVATIVE; MYC PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR PROTEIN; ZNF331 PROTEIN, HUMAN;

CELLS AND CELL COMPONENTS; GENE; GENE EXPRESSION; MEDICINE; PRECISION; PROTEIN; RODENT; SURVIVAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL DIVISION; CELL KILLING; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; ENGRAFTMENT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; K562 CELL LINE; LEUKAPHERESIS; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; RNA SEQUENCE; SPLEEN SIZE; TRANSCRIPTOMICS; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DEATH; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GENETICS; HEMATOPOIETIC STEM CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PATHOLOGY; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TRANSPLANTATION;

MUS;

ACETAMIDES; ANIMALS; ANTIGENS, CD34; AZEPINES; CELL DEATH; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; FEMALE; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; IMATINIB MESYLATE; IMIDAZOLINES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-MYC; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84975862388     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature18288     Document Type: Article

References (57)

1. O'Hare, T., Zabriskie, M. S., Eiring, A. M. & Deininger, M. W. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nature Rev. Cancer 12, 513-526 (2012).
2. Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001).
3. Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325 (2002).
4. Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029-1035 (2010).
5. Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396-409 (2011).
6. Neviani, P. et al. PP2A-Activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J. Clin. Invest. 123, 4144-4157 (2013).
7. Dijkstra, E. W. A note on two problems in connexion with graphs. Numer. Math. 1, 269-271 (1959).
8. Van Dang, C. & McMahon, S. B. Emerging concepts in the analysis of transcriptional targets of the MYC oncoprotein: Are the targets targetable? Genes Cancer 1, 560-567 (2010).
9. Boichenko, A. P. et al. A panel of regulated proteins in serum from patients with cervical intraepithelial neoplasia and cervical cancer. J. Proteome Res. 13, 4995-5007 (2014).
10. Liu, Y. et al. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-Acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol. Cell. Proteomics 13, 1753-1768 (2014).
11. Sutton, C. W. et al. Quantitative proteomic profiling of matched normal and tumor breast tissues. J. Proteome Res. 9, 3891-3902 (2010).
12. Pierce, A. et al. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol. Cell. Proteomics 7, 853-863 (2008).
13. Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nature Med. 10, 1321-1328 (2004).
14. Wong, C. et al. The bromodomain and extra-Terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death Dis. 5, e1450 (2014).
15. Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108, 16669-16674 (2011).
16. Hamilton, A. et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501-1510 (2012).
17. Li, L. et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21, 266-281 (2012).
18. Shah, N. P. et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485-493 (2008).
19. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446 (2010).
20. Yong, A. S., Szydlo, R. M., Goldman, J. M., Apperley, J. F. & Melo, J. V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 107, 205-212 (2006).
21. McWeeney, S. K. et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 115, 315-325 (2010).
22. Tovar, C. et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 73, 2587-2597 (2013).
23. Albrecht, B. K. et al. Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-Terminal (BET) family as a candidate for human clinical trials. J. Med. Chem. 59, 1330-1339 (2016).
24. Zhang, B. et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17, 427-442 (2010).
25. Hurtz, C. et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J. Exp. Med. 208, 2163-2174 (2011).
26. Lanza, F. & Bi, S. Role of p53 in leukemogenesis of chronic myeloid leukemia. Stem Cells 13, 445-452 (1995).
27. Gómez-Casares, M. T. et al. MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1). Oncogene 32, 2239-2246 (2013).
28. Winter, G. E. et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nature Chem. Biol. 8, 905-912 (2012).
29. Takeishi, S. et al. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 23, 347-361 (2013).
30. Reavie, L. et al. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell 23, 362-375 (2013).
31. Dang, C. V. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb. Perspect. Med. 3, a014217 (2013).
32. Vousden, K. H. & Prives, C. Blinded by the light: The growing complexity of p53. Cell 137, 413-431 (2009).
33. Wade, M., Li, Y. C. & Wahl, G. M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature Rev. Cancer 13, 83-96 (2013).
34. Zhang, H., Li, H., Ho, N., Li, D. & Li, S. Scd1 plays a tumor-suppressive role in survival of leukemia stem cells and the development of chronic myeloid leukemia. Mol. Cell. Biol. 32, 1776-1787 (2012).
35. Hsu, T. Y. et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525, 384-388 (2015).
36. Koh, C. M. et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature 523, 96-100 (2015).
37. Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538-542 (2015).
38. Prost, S. et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature 525, 380-383 (2015).
39. Pizzatti, L., Sá, L. A., de Souza, J. M., Bisch, P. M. & Abdelhay, E. Altered protein profile in chronic myeloid leukemia chronic phase identified by a comparative proteomic study. Biochim. Biophys. Acta 1764, 929-942 (2006).
40. Cramer-Morales, K. et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 122, 1293-1304 (2013).
41. Diaz-Blanco, E. et al. Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 21, 494-504 (2007).
42. Affer, M. et al. Gene expression differences between enriched normal and chronic myelogenous leukemia quiescent stem/progenitor cells and correlations with biological abnormalities. J. Oncol. 2011, 798592 (2011).
43. Graham, S. M., Vass, J. K., Holyoake, T. L. & Graham, G. J. Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 25, 3111-3120 (2007).
44. Huber, W., von Heydebreck, A., Söltmann, H., Poustka, A. & Vingron, M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18 (suppl. 1), S96-S104 (2002).
45. Smyth, G. K. in Bioinformatics and Computational Biology Solutions using R and Bioconductor (eds Gentleman, R., Dudoit, S., Irizarry, R. & Huber, W.) 397-420 (Springer, 2005).
46. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300 (1995).
47. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118-127 (2007).
48. Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).
49. Smyth, G. K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, e3 (2004).
50. Clark, A. G. et al. Inferring nonneutral evolution from human-chimp-mouse orthologous gene trios. Science 302, 1960-1963 (2003).
51. Xu, X. L. et al. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell 137, 1018-1031 (2009).
52. Wolfer, A. et al. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc. Natl Acad. Sci. USA 107, 3698-3703 (2010).
53. Sheth, A. et al. Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers. Cell Death Dis. 5, e1152 (2014).
54. Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-And-vote. Nucleic Acids Res. 41, e108 (2013).
55. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923-930 (2014).
56. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).
57. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).